Skip to main content

Psoriatic arthritis

      The dynamic Dr. Vinod Chandran, talking about metabolomics in #psoriaticDisease
      #ACR23
      The metabolomics facility was es

      Nigil Haroon MD, PhD, DM, FRCPC, FRCP, MBA NigilHaroon

      1 year 7 months ago
      The dynamic Dr. Vinod Chandran, talking about metabolomics in #psoriaticDisease #ACR23 The metabolomics facility was established recently at the @UHN @UofT @SchroederInst and we are already seeing the results. @KrembilF @CRASCRRheum @UofTRheum https://t.co/Azxq3k8w5g
      Large French study on infection risk of PsA biologics
      12k pts over 6 years
      When compared to Humira, only Enbrel and Ste

      Robert B Chao, MD

      1 year 7 months ago
      Large French study on infection risk of PsA biologics 12k pts over 6 years When compared to Humira, only Enbrel and Stelara had lower infection risk Concurrent steroid use associated with increased infection 1.85HR @RheumNow #ACR23 Abs#2566 https://t.co/Os1esuodfl
      Bastard et al. 12,071 French PsA. Low incidence serious infections on advanced therapy - 17 per 1,000 person-years. Sign

      Richard Conway

      1 year 7 months ago
      Bastard et al. 12,071 French PsA. Low incidence serious infections on advanced therapy - 17 per 1,000 person-years. Significantly lower risk ETN (HR 0.70), UST (HR 0.56) vs ADA. Others similar. Abstr#2566 #ACR23 @RheumNow https://t.co/GGDvRxP9ht https://t.co/Ol7G1OG73t
      Do Probiotics Improve PsA?
      Probiotics and gut microbiome is a hot topic in the research world and amongst patients. Oft

      Dr. John Cush RheumNow

      1 year 7 months ago
      Do Probiotics Improve PsA? Probiotics and gut microbiome is a hot topic in the research world and amongst patients. Often, one the questions I get after sharing the diagnosis of PsA is, “Is there anything I can eat/not eat to make this better?” #ACR23 https://t.co/aK56UXz3gs https://t.co/p2AuzcWyq9
      In this Ph2b RCT of TAK-279 (TYK2i), pts w/ PsA given 15mg & 30mg achieved an ACR20 response at wk 12 vs. PBO(53.3%

      sheila

      1 year 7 months ago
      In this Ph2b RCT of TAK-279 (TYK2i), pts w/ PsA given 15mg & 30mg achieved an ACR20 response at wk 12 vs. PBO(53.3% and 54.2% vs 29.2%, both p = 0.002) ⬆️common TEAEs: Npharyngitis, URTI, headache & rash #ACR23 ABSL12 @RheumNow https://t.co/T6swJgw6vE
      Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY

      Mithu Maheswaranathan, MD

      1 year 7 months ago
      Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY
      Daily Recap - TUESDAY https://t.co/Vq5BSHmPsv

      Dr. John Cush RheumNow

      1 year 7 months ago
      Daily Recap - TUESDAY https://t.co/Vq5BSHmPsv
      Does clinical enthesitis correlate with ultrasound enthesitis in psoriatic pts?
      52 wk study randomized to secukinumab or

      Robert B Chao, MD

      1 year 7 months ago
      Does clinical enthesitis correlate with ultrasound enthesitis in psoriatic pts? 52 wk study randomized to secukinumab or placebo found a long-term stable response of enthesitis control BUT NO correlation between clinical & US enthesitis @RheumNow #ACR23 Abs#2243 https://t.co/H7pESzYrNi
      Persistence of IL-17i vs. TNFi in PsA treatment

      Large database study
      Persistence of IL-17i slightly greater than TNFi

      Robert B Chao, MD

      1 year 7 months ago
      Persistence of IL-17i vs. TNFi in PsA treatment Large database study Persistence of IL-17i slightly greater than TNFi over 12 months Are IL-17i a better longterm strategy for PsA pts? @RheumNow #ACR23 Abs# 2240 https://t.co/9km5XgXcLE
      Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely

      Janet Pope

      1 year 7 months ago
      Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR
      Comorbidities, including heightened CV risk, are linked to severe psoriasis. However, understanding subclinical CV disea

      RWCS RWCSmtg

      1 year 7 months ago
      Comorbidities, including heightened CV risk, are linked to severe psoriasis. However, understanding subclinical CV disease timing in psoriasis patients remains limited. Dr. Jack Cush at .@RheumNow explains why more research is needed in this area: https://t.co/3KqQavVEbP https://t.co/Xo8SH0RTh9
      ×